Stem Cell Derived Cardiomyocytes in Drug Safety Evaluations: Lessons Learned from the Comprehensive in Vitro Proarrhythmia Assay (CiPA) Initiative

Video   Oct 18, 2016

 

The Comprehensive in Vitro Proarrhythmia Assay (CiPA) represents a new paradigm for directly assessing proarrhythmic risk based upon mechanistic assessments of cellular proarrhythmia linked to Torsades-de-Pointes proarrhythmia. Human stem cell derived cardiomyocytes (hSC-CMs) play a critical role in this initiative, serving to confirm in silico reconstructions of electrophysiologic effects of drugs. The utility of this approach involves consideration of the higher throughput approaches to be used (multielectrode arrays or voltage-sensing optical technologies) as well as consideration of the ability of hSC-CM’s to faithfully and reproducibly recapitulate cellular proarrhythmic events. Multiple publications (as well as a HESI-CiPA Pilot study) point to the utility of hSC-CM’s to detect delayed repolarization as well as other repolarization abnormalities. However, such studies are typically small and conducted unblinded, with a potential bias in the selection of test agents that may not be fully characterized in regards to proarrhythmic risk ranking. Evolving datasets from an ongoing validation study with hSC-CM’s will provide an assessment of the utility of hSC-CM’s for evaluating proarrhythmic liabilities early in drug discovery as well as in later regulatory-approvals of new drugs.

 
 
 
 

Recommended Videos

Discussing the Neurogenesis Debate

Video

Do we or don't we make new neurons in adulthood? Two recent high-profile papers present conflicting arguments.

WATCH NOW

Blood, Rats and Anticoagulants: The Story of Warfarin

Video

The history of warfarin, one of the earliest anticoagulant drugs, is littered with the bodies of sick cows and poisoned rats. This animation tells the story of how a bloody beginning gave rise to a life-saving medication.

WATCH NOW

Introduction to Peptides and Proteins for Bioanalysis Using LC-MS

Video

Khalid Khan, Senior Manager Business Development, discusses the basic structure of amino acids, peptides, and proteins, including specific examples like monoclonal antibodies. The ionization and fragmentation of peptides and how they differ from small molecules is also discussed.

WATCH NOW

 

Comments | 0 ADD COMMENT

Like what you just watched? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE